REG - Hikma Pharmaceutical - Result of AGM
RNS Number : 5097LHikma Pharmaceuticals Plc30 April 2020
Hikma Pharmaceuticals PLC
Voting Results of 2020 Annual General Meeting
LONDON, 30 April 2020 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BB+/positive S&P) announces its Annual General Meeting ("AGM"), held at 22 Regent Road, Surbiton KT5 8NL on 30 April 2020 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 18 were passed as ordinary resolutions and Resolutions 19 to 22 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 26 February 2020) is set out below. The number of Ordinary Shares in issue on 30 April 2020 was 242,543,355.
Resolution
Votes For
%
Votes Against
%
Total Cast
Withheld
1. To receive the 2019 report and accounts
201,698,273
99.99
57
0.01
201,698,330
1,120,694
2. To approve a final dividend of 30 cents per share
202,811,365
99.99
6,764
0.01
202,818,129
895
3. To re-appoint PricewaterhouseCoopers LLP as auditors
202,808,789
99.99
8,990
0.01
202,817,779
1,245
4.To authorise the Audit Committee to determine the auditors' remuneration
202,814,187
99.99
3,664
0.01
202,817,851
1,173
5. To elect Cynthia Schwalm as a director
201,548,814
99.37
1,268,304
0.63
202,817,118
1,906
6. To re-elect Said Darwazah as a director
196,190,726
96.77
6,538,997
3.23
202,729,723
89,301
7. To re-elect Siggi Olafsson as a director
200,700,552
98.96
2,117,034
1.04
202,817,586
1,438
8. To re-elect Mazen Darwazah as a director
197,442,264
97.35
5,375,322
2.65
202,817,586
1,438
9. To re-elect Robert Pickering as a director
196,820,454
97.04
5,996,664
2.96
202,817,118
1,906
10.To re-elect Ali Al-Husry as a director
199,416,313
98.32
3,401,273
1.68
202,817,586
1,438
11. To re-elect Patrick Butler as a director
199,744,398
98.48
3,073,188
1.52
202,817,586
1,438
12. To re-elect Dr. Pamela Kirby as a director
195,639,660
96.46
7,177,925
3.54
202,817,585
1,438
13. To re-elect Dr. Jochen Gann as a director
199,704,876
98.47
3,112,710
1.53
202,817,586
1,438
14. To re-elect John Castellani as a director
199,425,273
98.80
2,426,100
1.20
201,851,373
967,651
15. To re-elect Nina Henderson as a director
200,433,121
98.82
2,384,465
1.18
202,817,586
1,438
16. To approve the remuneration policy
190,931,576
95.50
8,992,802
4.50
199,924,378
2,894,646
17. To approve the remuneration report for the year ended 31 December 2019
190,252,825
95.16
9,671,582
4.84
199,924,407
2,894,616
18. Authority to allot shares
177,783,521
87.66
25,033,088
12.34
202,816,609
2,415
19. To dis-apply pre-emption rights for general purposes
202,778,888
99.98
37,721
0.02
202,816,609
2,415
20. To dis-apply pre-emption rights for an acquisition or other capital investment
201,813,423
99.51
1,003,156
0.49
202,816,579
2,445
21. To authorise the Company to purchase its own shares
201,634,579
99.44
1,133,921
0.56
202,768,500
50,524
22. To authorise the Company to hold general meetings on no less than 14 clear days' notice
197,970,909
97.61
4,846,842
2.39
202,817,751
1,273
Declaration of final dividend
The dividend of 30 cents per share will be paid on 7 May 2020 to shareholders on the register on 20 March 2020. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.238806 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRAGSDIFSSESSEIL
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement